About: Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA
Creator	Hsueh, Po-Ren Su, Ih-Jen Chang, Shan-Chwen Yang, Jyh-Yuan Chen, Pei-Jer Yeh, Shiou-Hwei Yang, Wen-Zieh Huang, Li-Rung Chiu, Chi-Ming Huang, Wen-Hung
Source	Medline; PMC
abstract	Severe acute respiratory syndrome (SARS)‐CoV is a newly emerging virus that causes SARS with high mortality rate in infected people. To study the humoral responses against SARS‐CoV, we evaluated nucleocapsid (N) and spike (S) proteins‐specific antibodies in patients' sera by Western blotting and enzyme‐linked immunosorbent assay (ELISA). Recombinant N and S proteins of SARS‐CoV were purified from transformed E. coli. Serum specimens from 40 SARS‐CoV‐infected patients in the convalescent phase were analyzed by Western blotting using the purified antigens. Serial serum specimens from 12 RT‐PCR‐confirmed SARS patients were assayed by ELISA using the recombinant N protein as coated antigen. By Western blotting, 97.5% of the SARS patients were positive for N protein‐specific antibodies whereas only 47.5% of the samples were positive for S protein‐specific antibodies. Using N protein‐based ELISA, 10 out of the 12 patients were positive for N protein‐specific antibodies and 6 of them showed seroconversion at mean of 16 days after onset of fever. Immunoblotting was useful for detecting the humoral immune response after SARS‐CoV infection. Antibodies against SARS‐CoV N protein appear at the early stage of infection, therefore, N protein‐based ELISA could serve as a simple, sensitive, and specific test for diagnosing SARS‐CoV infection. J. Med. Virol. 73:338–346, 2004. © 2004 Wiley‐Liss, Inc.
has issue date	2004-05-24(xsd:dateTime)
bibo:doi	10.1002/jmv.20096
bibo:pmid	15170626
has license	no-cc
sha1sum (hex)	d71673ed571153f4536b1088d48bc2d5631ae5fa
schema:url	https://doi.org/10.1002/jmv.20096
resource representing a document's title	Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA
has PubMed Central identifier	PMC7167198
has PubMed identifier	15170626
schema:publication	J Med Virol
resource representing a document's body	covid:d71673ed571153f4536b1088d48bc2d5631ae5fa#body_text
is schema:about of	named entity 'assayed' named entity 'humoral immune response' named entity 'Serial' named entity 'Antibody' named entity 'ELISA' named entity 'IS A' covid:arg/d71673ed571153f4536b1088d48bc2d5631ae5fa named entity 'Severe acute respiratory syndrome (SARS)' named entity 'convalescent' named entity 'infection' named entity 'samples' named entity 'specimens' named entity 'virus' named entity 'proteins' named entity 'protein' named entity 'nucleocapsid' named entity 'Western blotting' named entity 'CoV' named entity 'infection' named entity 'antigens' named entity 'E. coli' named entity 'antigen' named entity 'infection' named entity 'SARS' named entity 'nucleocapsid' named entity 'enzyme-linked immunosorbent assay' named entity 'antibodies' named entity 'Serum' named entity 'protein' named entity 'nucleocapsid' named entity 'Immunoblotting' named entity 'antibodies' named entity 'antigen' named entity 'protein' named entity 'immune responses' named entity 'sonication' named entity 'infection' named entity 'seroepidemiology' named entity 'Western blotting' named entity '229E' named entity 'serological' named entity 'antibodies' named entity 'E. coli' named entity 'SARS-CoV' named entity 'antigen' named entity 'serum' named entity 'nucleocapsid' named entity 'antigens' named entity 'cDNA' named entity 'Taipei' named entity 'antibodies' named entity 'S45' named entity 'Taq DNA polymerase' named entity 'serum samples' named entity 'blood donors' named entity 'nucleocapsid' named entity 'viruses' named entity 'nucleocapsid' named entity 'protein' named entity 'immunization' named entity 'antigens' named entity 'HPLC' named entity 'kDa' named entity 'SARS-CoV' named entity 'nucleocapsid' named entity 'virus' named entity 'protein' named entity 'Serum samples' named entity 'IBV' named entity 'SARS-CoV' named entity 'metallopeptidase' named entity 'SARS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software